Tuesday, September 23, 2025
No Result
View All Result
patriotfinancial.net
  • Home
  • Mortgage
  • Real Estate
  • Financial
  • Stocks
  • Investing
  • Markets
  • Startups
  • Trading
  • Personal Finance
  • Home
  • Mortgage
  • Real Estate
  • Financial
  • Stocks
  • Investing
  • Markets
  • Startups
  • Trading
  • Personal Finance
No Result
View All Result
patriotfinancial.net
No Result
View All Result

Abbott Laboratories started at Outperform by Oppenheimer on favorable risk/reward By Investing.com

October 8, 2024
in Financial
Reading Time: 2 mins read
0 0
A A
0
Home Financial
Share on FacebookShare on Twitter

[ad_1]

Investing.com — Oppenheimer initiated protection of Abbott Laboratories (NYSE:) with an Outperform score and a worth goal of $130 in a word Tuesday, citing a positive threat/reward profile. 

Based on Oppenheimer, Abbott is positioned as a diversified healthcare big, combining a sturdy MedTech portfolio with non-MedTech operations. 

The agency notes that whereas Abbott faces some headwinds in its non-MedTech segments, significantly in pediatric vitamin and declining COVID-19 diagnostics, the corporate’s total outlook stays constructive.

They mentioned Abbott’s MedTech portfolio contributes about 45% of its world gross sales and is anticipated to develop at an 11-13% CAGR. 

Moreover, the agency highlights Abbott’s strategic pricing as a key driver of its market share development, noting, for example, that “pricing Libre ~50% decrease has shortly catapulted it to management standing,” resulting in a robust 15-20% CAGR in its diabetes phase. 

Abbott’s leadless pacemaker AVEIR can be anticipated to see development, leveraging a 2-4x worth uplift.

Innovation is one other main focus, with Oppenheimer pointing to Abbott’s robust product pipeline, together with launches like TriClip in TTVR, Amulet in LAAOS, and aspirin-free LVADs, as crucial to its long-term development potential. 

“Even in OTC CGM, ABT has caught as much as DXCM in accuracy,” famous the analysts, boosting confidence in Abbott’s means to compete in key markets.

Regardless of challenges in its non-MedTech companies, significantly attributable to litigation on the pediatric method aspect, Oppenheimer expects these headwinds to subside by FY26, easing comps and paving the best way for long-term top-line development.

With a disciplined method to M&A and sturdy free money circulation of $7.7 billion per 12 months, Oppenheimer believes Abbott is well-positioned for continued development, with anticipated EPS development of 12-15% within the coming years.

 

[ad_2]

Source link

Tags: AbbottFavorableInvesting.comLaboratoriesOppenheimeroutperformRiskrewardStarted
Previous Post

Coursera Review: Is It Legit? Pros, Cons, and Everything You Need to Know – Wall Street Survivor

Next Post

Earnings Preview: Johnson & Johnson bets on innovation to stay in growth mode | AlphaStreet

Related Posts

March CPI higher than expected, housing prices rise
Financial

March CPI higher than expected, housing prices rise

April 15, 2025
Wipro Q4 Preview: Profit may dip 1% QoQ to Rs 3,319 crore; muted revenue likely despite mega-deal push
Financial

Wipro Q4 Preview: Profit may dip 1% QoQ to Rs 3,319 crore; muted revenue likely despite mega-deal push

April 15, 2025
IndusInd Bank notes Rs 1,979 cr hit to net worth due to derivatives lapse, impact to reflect in FY25
Financial

IndusInd Bank notes Rs 1,979 cr hit to net worth due to derivatives lapse, impact to reflect in FY25

April 15, 2025
UniCredit gains German cartel office nod for Commerzbank stake hike
Financial

UniCredit gains German cartel office nod for Commerzbank stake hike

April 15, 2025
Dolly Khanna adds over 5 lakh shares in this smallcap stock, raises stake to 2.18%
Financial

Dolly Khanna adds over 5 lakh shares in this smallcap stock, raises stake to 2.18%

April 15, 2025
Japan’s population falls by half million as birth rate stays low
Financial

Japan’s population falls by half million as birth rate stays low

April 15, 2025
Next Post
Earnings Preview: Johnson & Johnson bets on innovation to stay in growth mode | AlphaStreet

Earnings Preview: Johnson & Johnson bets on innovation to stay in growth mode | AlphaStreet

The Pros and Cons of Self-Managing Your Rental Property (From Two Experienced Investors)

The Pros and Cons of Self-Managing Your Rental Property (From Two Experienced Investors)

RBC Capital Markets ranks each S&P sector

RBC Capital Markets ranks each S&P sector

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Trending
  • Comments
  • Latest
Activist Oasis suggests three steps to build shareholder value at embattled Kobayashi Pharmaceutical

Activist Oasis suggests three steps to build shareholder value at embattled Kobayashi Pharmaceutical

August 13, 2024
Value at Risk (VaR) Calculation: Formulas, Portfolio Tools, and Methods in Python and Excel

Value at Risk (VaR) Calculation: Formulas, Portfolio Tools, and Methods in Python and Excel

February 9, 2025
Renting vs. Buying a Home: 55 Pros and Cons

Renting vs. Buying a Home: 55 Pros and Cons

March 5, 2025
All 103 Baker Brothers Portfolio Stocks | Current 2023 Holdings

All 103 Baker Brothers Portfolio Stocks | Current 2023 Holdings

August 26, 2023
How Seattle’s economy is managing in this uncertain season

How Seattle’s economy is managing in this uncertain season

May 24, 2024
M S Swaminathan, scientist who made India self-sufficient in food dies

M S Swaminathan, scientist who made India self-sufficient in food dies

September 28, 2023
FHFA rolls out mortgage fraud tip line

FHFA rolls out mortgage fraud tip line

April 15, 2025
March CPI higher than expected, housing prices rise

March CPI higher than expected, housing prices rise

April 15, 2025
Wipro Q4 Preview: Profit may dip 1% QoQ to Rs 3,319 crore; muted revenue likely despite mega-deal push

Wipro Q4 Preview: Profit may dip 1% QoQ to Rs 3,319 crore; muted revenue likely despite mega-deal push

April 15, 2025
Just Listed | 5150 N Ocean Drive #1201

Just Listed | 5150 N Ocean Drive #1201

April 15, 2025
Former Tesla supply chain leaders create Atomic, an AI inventory solution | TechCrunch

Former Tesla supply chain leaders create Atomic, an AI inventory solution | TechCrunch

April 15, 2025
IndusInd Bank notes Rs 1,979 cr hit to net worth due to derivatives lapse, impact to reflect in FY25

IndusInd Bank notes Rs 1,979 cr hit to net worth due to derivatives lapse, impact to reflect in FY25

April 15, 2025

Get the latest news and follow the coverage of Mortgage and Real Estate, Financial. Stocks, Investing, Trading and more from the trusted sources.

CATEGORIES

  • Financial
  • Investing
  • Markets
  • Mortgage
  • Personal Finance
  • Real Estate
  • Startups
  • Stock Market
  • Trading
Please enable JavaScript in your browser to complete this form.
Loading

LATEST UPDATES

  • FHFA rolls out mortgage fraud tip line
  • March CPI higher than expected, housing prices rise
  • Wipro Q4 Preview: Profit may dip 1% QoQ to Rs 3,319 crore; muted revenue likely despite mega-deal push
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Terms and Conditions
  • Cookie Privacy Policy
  • Contact us

Copyright © 2023 patriotfinancial.net.
patriotfinancial.net is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Mortgage
  • Real Estate
  • Financial
  • Stocks
  • Investing
  • Markets
  • Startups
  • Trading
  • Personal Finance

Copyright © 2023 patriotfinancial.net.
patriotfinancial.net is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In